Keywords: cv, therapeutics, begins, ph, ii, cvt-3146, trial

CV Therapeutics begins Ph II CVT-3146 trial

Article | 23 August 2001

Print This

CV Therapeutics has initiated a Phase II clinical trial to determine thetolerability and effect on coronary blood flow in patients ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in